CORDIS
EU research results

CORDIS

English EN
FRAGments training NETwork

FRAGments training NETwork

Objective

The promise of more efficient lead discovery is fuelling the enthusiasm for fragment-based lead discovery (FBLD). In this approach, highly sensitive biochemical and biophysical screening technologies are being used to detect the low affinity binding of low molecular weight compounds (the so-called fragments) to protein targets that are involved in pathophysiological processes. By investigating the molecular interactions between fragment hit(s) and the target protein, a detailed understanding of the binding event is obtained. This enables the rational and efficient optimisation of the hit fragment. The optimised compounds represent high quality leads for drug development. The necessary FBLD technologies and approaches have emerged mainly from small and specialised biotech companies. At present, FBLD is being adopted throughout pharmaceutical sciences, including by pharmaceutical companies, SMEs and academic research groups. So far, the necessary training that is needed to obtain an holistic view of the possibilities and opportunities that FBLD provides is missing, most likely because the highly multidisciplinary nature of the FBLD work is difficult to capture within one (academic) institute. Therefore, we have established FragNet as a dedicated FBLD training network. The consortium consists of the most prominent pharmaceutical companies, biotech companies and academic groups that have jointly shaped the FBLD research area. FragNet is committed to train 15 ESRs in all facets of FBLD using the combined technologies, skills and knowledge. This will include both research (e.g., technologies on the interface of chemistry and biology) and transferable skill sets (e.g., writing, media training, entrepreneurship and thorough understanding of scientific knowledge transfer). This will enable the ESRs to excel in today’s drug discovery and chemical biology programmes that are performed in public and private organisations in the pharmaceutical sciences.

Coordinator

STICHTING VU

Address

De Boelelaan 1105
1081 Hv Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 021 497,12

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY OF YORK

United Kingdom

EU Contribution

€ 819 863,64

MAGYAR TUDOMANYOS AKADEMIA TERMESZETTUDOMANYI KUTATOKOZPONT

Hungary

EU Contribution

€ 447 827,04

UNIVERSITAT DE BARCELONA

Spain

EU Contribution

€ 495 745,92

VERNALIS (R&D) LIMITED

United Kingdom

EU Contribution

€ 273 287,88

ZOBIO BV

Netherlands

EU Contribution

€ 255 374,28

BEACTICA AB

Sweden

EU Contribution

€ 263 659,32

NOVARTIS PHARMA AG

Switzerland

EU Contribution

€ 265 226,76

Partners (5)

Sort alphabetically

Expand all

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

F. HOFFMANN-LA ROCHE AG

INSTITUT DE RECHERCHES SERVIER

IOTA Pharmaceuticals Ltd

24 Media Labs

Project information

Grant agreement ID: 675899

Status

Ongoing project

  • Start date

    1 March 2016

  • End date

    29 February 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 842 481,96

  • EU contribution

    € 3 842 481,96

Coordinated by:

STICHTING VU

Netherlands